ERBB2 and breast neoplasm: The use of tumour-to-contralateral site ratios 2 h after injection permitted discrimination between HER2-positive and HER2-negative primary breast tumours (p < 0.001, Mann–Whitney test) when the optimal ADAPT6 mass (500 μg) was injected [22].